九强生物(300406) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥372,581,948.21, a decrease of 0.29% compared to ¥373,680,102.50 in the same period last year[3] - Net profit attributable to shareholders was ¥98,110,266.08, down 12.53% from ¥112,160,261.95 year-on-year[3] - The basic earnings per share for Q1 2022 was ¥0.17, down 10.53% from ¥0.19 in the same period last year[3] - Net profit for the current period was ¥100,302,531.25, down 25.34% from ¥134,358,180.49 in the previous period[32] - Earnings per share (basic and diluted) were both ¥0.17, compared to ¥0.19 in the previous period[35] - The company recorded a total profit of ¥116,819,840.19, down from ¥154,611,662.53 in the previous period, indicating a decline of 24.48%[32] Cash Flow - The net cash flow from operating activities improved significantly to ¥12,395,647.70, compared to a negative cash flow of ¥18,666,833.49 in the previous year, representing a 166.40% increase[3] - Cash inflow from operating activities totaled approximately $369.73 million, an increase of 28.7% compared to $287.42 million in the previous period[39] - The company reported a net cash flow from operating activities of approximately $12.40 million, a turnaround from a negative cash flow of -$18.67 million in the previous period[39] - Cash received from sales of goods and services was approximately $366.85 million, compared to $284.21 million in the previous period[39] - Net cash outflow from investing activities was approximately -$63.21 million, improving from -$83.71 million in the previous period[42] - Net cash outflow from financing activities was approximately -$76.28 million, a decline from a net inflow of $8.13 million in the previous period[42] - The net cash and cash equivalents decreased by approximately $127.20 million, compared to a decrease of $94.26 million in the previous period[42] - Cash and cash equivalents at the end of the period stood at approximately $255.32 million, down from $482.93 million in the previous period[42] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,302,187,620.39, a slight decrease of 0.41% from ¥4,319,709,471.19 at the end of the previous year[3] - Total liabilities decreased to ¥1,291,375,579.13 from ¥1,406,347,264.64, a reduction of 8.16%[28] - Total current liabilities of RMB 493,728,401.85, down from RMB 607,600,738.81, indicating a decrease of about 18.7%[22] - Non-current liabilities include long-term borrowings of RMB 766,100,000.00, remaining stable compared to RMB 766,400,000.00 at the beginning of the year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,748[10] - The largest shareholder, China Pharmaceutical Investment Co., Ltd., held 14.81% of the shares, totaling 87,209,302 shares[10] - The company repurchased a total of 561,200 shares, accounting for 0.0953% of the total share capital, with a total transaction amount of RMB 9,998,110[15] - The company plans to use between RMB 50 million and RMB 100 million for share repurchase, with a maximum repurchase price of RMB 20 per share[15] Expenses - Total operating costs increased to ¥259,727,100.76, up 17.06% from ¥221,862,090.95 in the previous period[29] - The company reported a significant increase in financial expenses, which rose by 707.80% to ¥1,261.90 from ¥156.21 year-on-year, primarily due to increased loan interest expenses[6] - The company reported a significant increase in sales expenses, which rose to ¥72,239,000.08, up 35.05% from ¥53,482,205.41 in the previous period[29] - Research and development expenses were reported at ¥31,483,397.75, an increase from ¥25,609,696.17 in the previous period[29] Equity - The equity attributable to shareholders increased by 3.31% to ¥2,969,635,748.37 from ¥2,874,365,713.69 at the end of the previous year[3] - Total equity increased to ¥3,010,812,041.26, up from ¥2,913,362,206.55, reflecting a growth of 3.38%[28] Inventory and Receivables - The company's inventory decreased to RMB 220,906,019.36 from RMB 252,007,871.96, reflecting a reduction of approximately 12.3%[19] - Accounts receivable increased to RMB 947,926,236.90 from RMB 917,342,741.14, showing a growth of about 3.5%[19] Acquisitions - The company completed the acquisition of 75% equity in Wuhan Huihai Pharmaceutical Technology Development Co., Ltd. for RMB 4,000,000[16] Government Subsidies - The company received government subsidies amounting to ¥2,076,962.70 during the reporting period[5]